BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 21315529)

  • 1. Gd-EOB-DTPA-enhanced MR imaging: evaluation of hepatic enhancement effects in normal and cirrhotic livers.
    Tamada T; Ito K; Higaki A; Yoshida K; Kanki A; Sato T; Higashi H; Sone T
    Eur J Radiol; 2011 Dec; 80(3):e311-6. PubMed ID: 21315529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gd-EOB-DTPA enhanced MR imaging: evaluation of biliary and renal excretion in normal and cirrhotic livers.
    Tamada T; Ito K; Sone T; Kanki A; Sato T; Higashi H
    Eur J Radiol; 2011 Dec; 80(3):e207-11. PubMed ID: 20869827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of liver cirrhosis on liver enhancement at Gd-EOB-DTPA enhanced MRI at 3 Tesla.
    Verloh N; Haimerl M; Rennert J; Müller-Wille R; Nießen C; Kirchner G; Scherer MN; Schreyer AG; Stroszczynski C; Fellner C; Wiggermann P
    Eur J Radiol; 2013 Oct; 82(10):1710-5. PubMed ID: 23806531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic parenchymal enhancement at Gd-EOB-DTPA-enhanced MR imaging: correlation with morphological grading of severity in cirrhosis and chronic hepatitis.
    Kanki A; Tamada T; Higaki A; Noda Y; Tanimoto D; Sato T; Higashi H; Ito K
    Magn Reson Imaging; 2012 Apr; 30(3):356-60. PubMed ID: 22227353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic contrast-enhanced magnetic resonance imaging of abdominal solid organ and major vessel: comparison of enhancement effect between Gd-EOB-DTPA and Gd-DTPA.
    Tamada T; Ito K; Sone T; Yamamoto A; Yoshida K; Kakuba K; Tanimoto D; Higashi H; Yamashita T
    J Magn Reson Imaging; 2009 Mar; 29(3):636-40. PubMed ID: 19243060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential clinical factors affecting hepatobiliary enhancement at Gd-EOB-DTPA-enhanced MR imaging.
    Higaki A; Tamada T; Sone T; Kanki A; Sato T; Tanimoto D; Higashi H; Ito K
    Magn Reson Imaging; 2012 Jun; 30(5):689-93. PubMed ID: 22459437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic hemangiomas: difference in enhancement pattern on 3T MR imaging with gadobenate dimeglumine versus gadoxetate disodium.
    Gupta RT; Marin D; Boll DT; Husarik DB; Davis DE; Feuerlein S; Merkle EM
    Eur J Radiol; 2012 Oct; 81(10):2457-62. PubMed ID: 22138122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver vessel enhancement by Gd-BOPTA and Gd-EOB-DTPA: a comparison in healthy volunteers.
    Brismar TB; Dahlstrom N; Edsborg N; Persson A; Smedby O; Albiin N
    Acta Radiol; 2009 Sep; 50(7):709-15. PubMed ID: 19701821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contrast enhanced liver MRI in patients with primary sclerosing cholangitis: inverse appearance of focal confluent fibrosis on delayed phase MR images with hepatocyte specific versus extracellular gadolinium based contrast agents.
    Husarik DB; Gupta RT; Ringe KI; Boll DT; Merkle EM
    Acad Radiol; 2011 Dec; 18(12):1549-54. PubMed ID: 21958599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of three different injection methods for arterial phase of Gd-EOB-DTPA enhanced MR imaging of the liver.
    Tamada T; Ito K; Yoshida K; Kanki A; Higaki A; Tanimoto D; Higashi H
    Eur J Radiol; 2011 Dec; 80(3):e284-8. PubMed ID: 21296514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects.
    Dahlström N; Persson A; Albiin N; Smedby O; Brismar TB
    Acta Radiol; 2007 May; 48(4):362-8. PubMed ID: 17453513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
    Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
    Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement?
    Motosugi U; Ichikawa T; Sou H; Sano K; Tominaga L; Kitamura T; Araki T
    J Magn Reson Imaging; 2009 Nov; 30(5):1042-6. PubMed ID: 19856436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T2-weighted magnetic resonance imaging of the liver: evaluation of the effect in signal intensity after Gd-EOB-DTPA enhancement.
    Tamada T; Ito K; Yoshida K; Sone T; Murakami K; Kanki A; Watanabe S; Higashi H; Yamashita T
    J Comput Assist Tomogr; 2010; 34(2):182-6. PubMed ID: 20351500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gd-EOB-DTPA-enhanced MR imaging: prediction of hepatic fibrosis stages using liver contrast enhancement index and liver-to-spleen volumetric ratio.
    Goshima S; Kanematsu M; Watanabe H; Kondo H; Kawada H; Moriyama N; Bae KT
    J Magn Reson Imaging; 2012 Nov; 36(5):1148-53. PubMed ID: 22848019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Which is the best MRI marker of malignancy for atypical cirrhotic nodules: hypointensity in hepatobiliary phase alone or combined with other features? Classification after Gd-EOB-DTPA administration.
    Golfieri R; Grazioli L; Orlando E; Dormi A; Lucidi V; Corcioni B; Dettori E; Romanini L; Renzulli M
    J Magn Reson Imaging; 2012 Sep; 36(3):648-57. PubMed ID: 22592930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New proposal for the staging of nonalcoholic steatohepatitis: evaluation of liver fibrosis on Gd-EOB-DTPA-enhanced MRI.
    Tsuda N; Okada M; Murakami T
    Eur J Radiol; 2010 Jan; 73(1):137-42. PubMed ID: 19026502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging predicts the histological grade of hepatocellular carcinoma only in patients with Child-Pugh class A cirrhosis.
    Kim HY; Choi JY; Kim CW; Bae SH; Yoon SK; Lee YJ; Rha SE; You YK; Kim DG; Jung ES
    Liver Transpl; 2012 Jul; 18(7):850-7. PubMed ID: 22407909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contrast agent Gd-EOB-DTPA (EOB·Primovist®) for low-field magnetic resonance imaging of canine focal liver lesions.
    Yonetomi D; Kadosawa T; Miyoshi K; Nakao Y; Homma E; Hanazono K; Yamada E; Nakamura K; Ijiri A; Minegishi N; Maetani S; Hirayama K; Taniyama H; Nakade T
    Vet Radiol Ultrasound; 2012; 53(4):371-80. PubMed ID: 22548505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB-DTPA.
    Frericks BB; Loddenkemper C; Huppertz A; Valdeig S; Stroux A; Seja M; Wolf KJ; Albrecht T
    AJR Am J Roentgenol; 2009 Oct; 193(4):1053-60. PubMed ID: 19770329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.